Patent Description:
The present disclosure relates to a customizable facility that enables a user to manufacture multiple products within the facility. In particular, the present disclosure relates to a customizable facility according to claim <NUM> for manufacturing products in clean room settings and a method according to claim <NUM> of assembling such a facility.

Traditional structures for manufacturing products, such as monoclonal antibodies and microbial products, do not allow for efficient use of the space of the structure. The layout of traditional structures often limits them from being readily configured or expanded to manufacture a new product line. Thus, there is a need for a manufacturing facility that allows a user to efficiently use common resources between product lines and readily modify the facility to accommodate a new manufacturing process or a new manufacturing line with reduced facility down time. Examples of such manufacturing structures according to the state of the art are disclosed in <CIT>, <CIT>, <CIT> and <CIT>.

The present disclosure provides a customizable facility for manufacturing at least one product, utilizing at least one production process (e.g., a production process using a fermentation unit and a purification unit). In particular the invention relates to a customizable facility according to claim <NUM> and a method according to claim <NUM> of assembling such a facility.

According to one aspect of the present disclosure, the customizable facility includes a shell, at least one central unit positioned within the shell, and at least one modular unit, each modular unit being positioned within the shell. The shell, the central unit(s), and the modular unit(s) are configured and arranged to maximize the speed and ease of modifying manufacturing capacity of varying scope.

According to another aspect of the present disclosure, a customizable facility for manufacturing at least one pharmaceutical product, includes at least one central unit. At least one modular unit is in communication with the at least one central unit such that the at least one central unit provides utilities to the at least one modular unit.

In some embodiments, the customizable facility includes a shell, wherein the at least one central unit is positioned at least partially within the shell and the at least one modular unit is positioned at least partially within the shell.

In some embodiments, the at least one modular unit includes at least one of a fermentation unit, a pre-viral unit, a post-viral unit, a utility space, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a fill-finish unit, a dosage formulation unit, and a packaging unit.

In some embodiments, at least one of the at least one modular unit is directly adjacent to the at least one central unit.

In some embodiments, the at least one modular unit includes a plurality of modular units arranged to maximize a number of modular units within the shell while minimizing a footprint of the shell.

In some embodiments, each modular unit of the plurality of modular units is directly adjacent at least one of the at least one central unit and another one of the plurality of modular units.

In some embodiments, the at least one central unit and the plurality of modular units form a hub and spoke formation.

In some embodiments, the at least one central unit and the plurality of modular units are arranged in an H-shaped layout.

In some embodiments, the customizable facility includes a bioreactor supported on a ground surface within the shell.

In some embodiments, the customizable facility includes a bioreactor supported within one of the at least one modular unit.

In some embodiments, an outer wall of the customizable facility is one of: formed by the shell, the shell entirely enclosing the at least one central unit and the at least one modular unit; and formed by the shell and at least one of an outer wall of the at least one central unit and an outer wall of the at least one modular unit.

In some embodiments, the shell includes at least one side wall, the at least one side wall encircling the at least one central unit and the at least one modular unit, and a roof secured to an upper edge of the at least one side wall, the roof extending over the at least one central unit and the at least one modular unit.

In some embodiments, at least one of the at least one modular unit is a clean room.

In some embodiments, the at least one modular unit is configured for cell therapy operations.

According to another aspect of the present disclosure, a method of assembling a facility for manufacturing at least one pharmaceutical product includes providing at least one central unit; and providing at least one modular unit in communication with the at least one central unit such that the at least one central unit provides utilities to the at least one modular unit.

In some embodiments, the method includes providing a shell; positioning the at least one central unit at least partially within the shell; and positioning the at least one modular unit at least partially within the shell.

According to the invention the at least one modular unit includes at least one of a fermentation unit, a pre-viral unit, a post-viral unit, a utility space, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a fill-finish unit, a dosage formulation unit, and a packaging unit.

In some embodiments, each modular unit of the plurality of modular units is directly adjacent at least one of the at least one central unit and another one of the at least one modular unit.

In some embodiments, the method includes one of supporting a bioreactor on a ground surface within the shell and supporting a bioreactor within one of the at least one modular unit.

In some embodiments, the at least one pharmaceutical product is a biosimilar product.

In the drawings:.

The structures disclosed herein for a customizable facility are useful for manufacturing at least one product at a given time. The structures disclosed herein are particularly useful for manufacturing a variety of products that utilize common resources.

The present disclosure provides systems and methods that allow for one or more scalable product lines to be at least partially enclosed within a shell of a customizable facility. Because the structure is adaptable, it does not require a user to commit the structure to a single product line for a long period of time. The structure can be reconfigured to meet the dimensional requirements of a product line.

The customizable facility of the present disclosure enables a user to decrease construction timelines, reduce capital expenditures, increase global design standardization, and to comply with various standards around the globe.

The customizable structure allows for shorter turnaround times from conception to construction, allows for decreased construction site congestion and requires fewer fixed assets when implementing a new product line.

Generally, the customizable facility comprises a shell, at least one central unit positioned within the shell, and at least one modular unit, each modular unit being positioned within the shell.

<FIG> is a top plan view of an exemplary embodiment of a customizable facility generally indicated at <NUM>. The customizable facility of <FIG> can be constructed in a series of phases, such as a first phase <NUM>, a second phase <NUM>, and subsequent phases.

The features installed in the first phase <NUM> of construction of the customizable facility <NUM> of <FIG> include an air controlled entryway <NUM>, a changing area <NUM>, a utilities area <NUM>, a first manufacturing wing 22A, a first office space 24A, and at least one corridor <NUM> allowing occupants of the customizable facility <NUM> to move within the customizable facility <NUM> from one area to another.

Outside of the customizable facility <NUM>, there is a yard <NUM> that includes a handling area <NUM> for handling equipment and materials. The yard area <NUM> is shown adjacent to a roadway <NUM>. Generally, the customizable facility <NUM> can be expanded in any direction. Additionally, the customizable facility <NUM> is constructed such that it can expand in a series of construction phases and/or sub-phases within the physical constraints of the surrounding features, such as the yard area <NUM> and the roadway <NUM>.

<FIG> shows additional features that can be added during a second phase <NUM> of construction, such as a second manufacturing wing 22B and a second office space 24B.

The layout of the customizable facility <NUM> can be configured for manufacturing in clean room settings. The customizable facility <NUM> utilizes a hybrid stick or frame build building and modular buildings with a utilities unit (or utility hub).

Referring now to <FIG>, the relative positions of various components of the customizable facility are shown.

<FIG> shows a perspective view of the exterior walls of the outer shell <NUM> of the customizable facility <NUM>. The outer shell (or shell) <NUM> at least partially encloses a central unit (which may be a central utilities unit) <NUM> and at least partially encloses a plurality of modular units <NUM>, as discussed further below. In some embodiments, the outer shell <NUM> entirely encloses the utilities unit (which may be a central utilities unit) <NUM> and entirely encloses the plurality of modular units <NUM>.

The outer shell <NUM> can be constructed according to traditional stick building or another method, such as, but not limited to, prefabricated modules. For example, the outer shell <NUM> can be fabricated from a steel structure using traditional building methods. The outer shell <NUM> can be supported on footings secured in the ground. The outer shell <NUM> is weatherproof.

The outer shell <NUM> forms a superstructure. In some embodiments, the outer shell <NUM> can be a "Butler" style building, which is known in the art of building construction.

The outer shell <NUM> includes side walls <NUM> that are dimensioned and configured to encircle one or more central units <NUM> and one or more modular units <NUM> included in the customizable facility <NUM>, and described in more detail below.

A roof <NUM> is secured to upper edges of the side walls <NUM>, with the roof <NUM> extending over the central unit(s) <NUM> and the modular unit(s) <NUM>. Thus, the side walls <NUM> and the roof <NUM> enclose the central unit(s) <NUM> and the modular unit(s) <NUM>, which are positioned within the shell <NUM>. The central unit(s) <NUM> and the modular unit(s) <NUM> may be supported on a floor of the shell <NUM> or on another support surface on which the shell is secured. The customizable facility <NUM> provides a partially-modular (what could be called a modular stick build) method that includes a basic superstructure that is then filled in with modular type elements.

In one embodiment, the customizable facility <NUM> of <FIG> has an outer height of <NUM> meters. In one embodiment, each manufacturing wing has a length of <NUM> meters and a width of <NUM> meters.

<FIG> shows the exterior of the customizable facility <NUM> in broken lines, with the utilities area in solid lines. The utilities area <NUM> can include a central unit (which may be referred to as a Central Utility Bay (CUB) or utilities building or central utility module) <NUM> that is positioned towards the middle of the customizable facility <NUM>.

The shell <NUM> of <FIG> also encloses a future utilities area <NUM>, which is fully occupied by a future utilities module in <FIG>. The future utilities area <NUM> is adjacent to the utilities module <NUM>, and is shown in <FIG>. The future utilities area <NUM> can be used as a warehouse area adjacent to the utilities module <NUM>. The future utilities area <NUM> within this customizable facility <NUM> could also suite high bay applications, such as a <NUM> foot tall warehouse having an automated search and retrieval system (ASARS).

In some embodiments, the utilities module <NUM> and the future utilities area <NUM> are a single utilities module, which is divided into a utilities section and a future utilities section.

The central utility module <NUM> does not need to be at the center of the customizable facility <NUM>. The central utility module <NUM> can be positioned along an outer edge of the customizable facility <NUM> in some embodiments.

<FIG> shows the exterior of the customizable facility <NUM> in broken lines, with the manufacturing wings 22A, 22B in solid lines.

The manufacturing wings 22A, 22B are configured to contain modular units <NUM> for a product line, such as fermentation modules or purification modules. The customizable facility <NUM> is easily expandable and scalable, and the different modular units <NUM> within the manufacturing wings 22A, 22B can be used to produce completely different products in the same customizable facility <NUM>.

For example, in a modular unit <NUM> configured as a first fermentation module, a user could be manufacturing one type of product, such as a monoclonal antibody product derived from a mammalian cell line. In a second modular unit <NUM>, the user could manufacture a completely different product, such as a microbial product. The customizable facility <NUM> of the present disclosure is capable of supporting multiple product lines simultaneously and multiple customers from a single, expandable superstructure. The customizable facility <NUM> of the present disclosure is capable of being expanded to add additional product lines.

Reactors can be supported within the modular units <NUM> of the manufacturing wings 22A, 22B of the customizable facility <NUM>. The customizable facility <NUM> can support any desired and suitable vessel volume. For example, in some aspects such as that shown in <FIG>, the customizable facility <NUM> can be configured to contain up to <NUM>,<NUM> liter production vessels, and storage vessels (e.g., harvest) in excess of <NUM>,<NUM> liters (e.g., <NUM>,<NUM> - <NUM>,<NUM> liters). For example, the customizable facility <NUM> can be dimensioned and configured to support vessels having a volume of about <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters and/or <NUM>,<NUM> liters. Vessels having other volumes can also be supported.

Any typical manufacturing and clean room equipment can be included in the customizable facility <NUM>, and the customizable facility <NUM> can be fully suitable for cGMP (current good manufacturing practice) processes.

Examples of some equipment that can be fit in the customizable facility <NUM> include, but are not limited to: bioreactor, disc stack centrifuge, tangential flow filtration (TFF) skid, depth filtration skid, in-line dilution skid, chromatography columns with associated control equipment, media tank, harvest tank, purification vessels, depth filter holders, water softening and dechlorination system, clean steam generator, water for injection (WFI) storage tank, WFI break tank, WFI still, cooling towers, switchboard, emergency generator, chiller, hydronic pumps, autoclave, air handling units, process waste neutralization (such as a fiberglass reinforced plastic (FRP)), biowaste collection and inactivation system, clean-in-place systems, glass washer, and/or other equipment.

Bioreactors in the customizable facility <NUM> of the present disclosure can be ground based reactors. Alternatively, the bioreactors could be suspended from the structure itself. For example, the bioreactors could be suspended from one or more of the modular units <NUM>.

The customizable facility <NUM> can include one or more central unit <NUM> and one or more modular unit <NUM>. In some embodiments, each modular unit <NUM> is selected from the group of: a fermentation or cell culture unit, a pre-viral unit, a post-viral unit, a utility yard, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a fill-finish unit, a dosage formulation unit, and a packaging unit. A production unit is useful for manufacturing a product. A fill-finish unit is useful for filling a container such as a vial. A dosage formulation unit dispenses a set dose of a product. A packaging unit packages a product for distribution or sale.

The space allocated for each modular unit can be divided further as needed to fit specific processing requirements. Each manufacturing wing 22A, 22B can be configured to allow more than one modular unit <NUM> to be positioned within the respective manufacturing wing 22A, 22B.

In <FIG> and <FIG>, a first manufacturing wing 22A comprises three modular units <NUM>. A second manufacturing wing 22B comprises two modular units <NUM>. The central utilities area <NUM> has a length of <NUM> meters and a width of <NUM> meters, and has three internal levels. The central utilities block is expandable.

In some embodiments, at least one of the modular units <NUM> is a clean room. In some embodiments, at least one of the modular units <NUM> includes a clean room section within the respective modular unit <NUM>.

The building shell <NUM> is designed to accommodate different production modules. In some embodiments, the shell can house four <NUM>,<NUM> liter vessels for a mammalian cell line. In some embodiments, the shell can house four <NUM>,<NUM> liter vessels for single-use technology operations.

In some embodiments, a manufacturing wing can include a modular unit containing four <NUM>,<NUM> liter vessels and downstream processing equipment and configured for manufacturing a monoclonal antibody product derived from a mammalian cell line, a modular unit containing single-use equipment for manufacturing a monoclonal antibody product derived from a mammalian cell line having four <NUM>,<NUM> liter vessels, a modular unit configured for manufacturing a microbial product, and/or a modular unit containing single-use equipment for manufacturing a microbial product.

In one embodiment, a modular unit is configured for mammalian manufacturing and includes four <NUM>,<NUM> liter vessels and downstream processing equipment. In another embodiment, a modular unit includes four <NUM>,<NUM> liter vessels for commercial and clinical production. In another embodiment, a modular unit includes one <NUM>,<NUM> liter vessel for clinical production. In another embodiment, a modular unit is configured for manufacturing a microbial product, and includes one <NUM>,<NUM> liter vessel. In another embodiment, a modular unit includes three <NUM>,<NUM> liter vessels. In another embodiment, a modular unit includes one or more process development labs. In another embodiment, a modular unit includes fill and finish clinical development vial fill equipment, one or more set of lyophilizing equipment, equipment for manufacturing pre-filled syringes, and/or equipment for manufacturing high potency products for commercial applications. In some embodiments, a modular unit includes cell therapy equipment. In some embodiments, a modular unit includes viral therapy equipment.

<FIG> shows the exterior of the customizable facility <NUM> in broken lines, with the first office space 24A and the second office space 24B in solid lines. The first office space 24A includes offices, lockers for personal storage, and a support area. The second office space 24B includes offices, lockers for personal storage, and a support area. The front wall 48A of the first office space 24A forms a portion of the front outer surface of the customizable facility <NUM>, as shown in <FIG>. The front wall 48B of the first office space 24B forms a portion of the front outer surface of the customizable facility <NUM>. Thus, each office space 24A, 24B is only partially enclosed by the shell <NUM> of the customizable facility <NUM>.

Similarly, in some embodiments, an outer wall of the central unit and/or an outer wall of one of the at least one modular units forms at least a part of the outer wall of the customizable facility. In some embodiments, an upper surface of a central utility module and/or an upper surface of a modular unit forms part of an upper surface of the customizable facility.

<FIG> shows the exterior of the customizable facility <NUM> in broken lines, with the changing area <NUM> in solid lines. The changing area <NUM> allows users to enter the customizable facility <NUM> and change from street clothes into work clothes. The changing area <NUM> in <FIG> is further subdivided into a male changing area 18A and a female changing area 18B. In some embodiments, the changing area <NUM> is subdivided into two or more changing areas. In some embodiments, the changing area <NUM> is not subdivided.

In other embodiments, the relative positions of the first manufacturing wing 22A and second manufacturing wings 22B, the first office space 24A, the second office space 24B, the changing area <NUM>, and the utilities area <NUM> can be positioned differently in the customizable facility <NUM> and/or oriented differently with respect to the customizable facility <NUM>.

Scaffolding and corridors <NUM> allow users of the customizable facility <NUM> to access the utilities unit <NUM> of the utilities area <NUM> and the modular units (fermentation, etc. modules) <NUM>.

After adding the second phase <NUM> of construction to the customizable facility <NUM>, over time a user may wish to further expand the customizable facility <NUM>. For example, consumers in the global economy may develop increased demand for a product that the user is manufacturing, or consumers in the global economy may develop increased demand for a product that the user could produce. To respond to such increases in demand for a product, the user can expand the customizable facility <NUM> in subsequent phases of construction that add additional features to the customizable facility of <FIG>. In some embodiments, such additional features (such as additional modular units, an additional manufacturing wing, or another component of a customizable facility) are positioned horizontally adjacent to the first manufacturing wing 22A or the second manufacturing wing 22B. In some embodiments, such additional features are positioned vertically adjacent to the first manufacturing wing 22A and/or the second manufacturing wing 22B.

Referring now to <FIG>, it is possible for a user to expand a manufacturing wing, such as the first manufacturing wing 22A or the second manufacturing wing 22B of <FIG>, in different sub-phases. A user could convert a manufacturing wing layout from one of the configurations shown in <FIG> to another configuration shown in <FIG>. Alternatively, a user could convert a manufacturing wing layout to another configuration.

<FIG> shows a partially exploded view of an embodiment of a modular unit 40A that is configured as a fill finish module. The fill finish module of <FIG> has a single floor 60A with a footprint of <NUM>,<NUM> square meters. The fill finish module includes a mezzanine for an HVAC plant room and some localized utilities. A free field 50A is shown in broken lines adjacent to the fill finish module, and has a footprint of <NUM>,<NUM> square meters. The free field 50A can be used for a variety of purposes, such as product storage. Together, the fill finish module 40A and the free field 50A extend over the <NUM>,<NUM> square meter footprint of the second manufacturing wing 22B.

<FIG> shows a partially exploded view of an embodiment of a modular unit 40B that is configured as a "<NUM> module. " The <NUM> module of <FIG> has a single floor 60B with a footprint of <NUM>,<NUM> square meters. The <NUM> module can enclose a <NUM>,<NUM> liter vessel. The <NUM> module includes a mezzanine for an HVAC plant room and some localized utilities. A free field 50B is shown in broken lines adjacent to the <NUM> module, and has a footprint of <NUM>,<NUM> square meters. The free field 50B can be used for a variety of purposes, such as product storage. Together, the <NUM> module 40B and the free field 50B extend over the <NUM>,<NUM> square meter footprint of the second manufacturing wing 22B.

<FIG> shows a partially exploded view of an embodiment of a modular unit 40C that is configured as "a <NUM> module. " The <NUM> module of <FIG> has a single floor 60C with a footprint of <NUM>,<NUM> square meters. The <NUM> module can enclose a <NUM>,<NUM> liter vessel. The <NUM> module includes a mezzanine for an HVAC plant room and some localized utilities. The <NUM> module extends over the <NUM>,<NUM> square meter footprint of the manufacturing wing.

<FIG> shows a partially exploded view of an embodiment of a modular unit 40D that is configured as a "<NUM> module. " The <NUM> module of <FIG> has a first floor 60D and a second floor <NUM>. The <NUM> module of <FIG> has a footprint of <NUM>,<NUM> square meters. The <NUM> module can enclose a <NUM>,<NUM> liter vessel. The <NUM> module includes a local HVAC unit, a clean in place (CIP) unit, and a temperature control unit (TCU). The temperature control unit in some embodiments includes water jackets with heat exchangers on a tank to control the temperature of a tank used in a product line. A CIP unit is typically a modular skid and has several tanks to hold a cleaning solution (such as caustic solutions and bleach), pumps, and sensors to send the cleaning solution to the appropriate tank to be cleaned.

The first floor 60D of the <NUM> module extends over the <NUM>,<NUM> square meter footprint of the manufacturing wing. The second floor <NUM> of the <NUM> module extends vertically above the first floor of the <NUM> module, and extends above the <NUM>,<NUM> square meter footprint of the manufacturing wing. Together, the first floor 60D of the <NUM> module and the second floor <NUM> of the <NUM> module have a combined area of <NUM>,<NUM> square meters.

<FIG> shows a partially exploded view of an embodiment of a modular unit 40E that is configured as a "<NUM> module. " The <NUM> module of <FIG> has a footprint of <NUM>,<NUM> square meters. The <NUM> module can enclose a <NUM>,<NUM> liter vessel. The <NUM> module includes a local HVAC unit, a CIP unit, and a TCU. The <NUM> module includes a first floor, a second floor, and a third floor. The first floor 60E of the <NUM> module extends over the <NUM>,<NUM> square meter footprint of the manufacturing wing. The second floor <NUM> of the <NUM> module extends vertically above the first floor 60E of the <NUM> module, and extends above the <NUM>,<NUM> square meter footprint of the manufacturing wing. The third floor <NUM> of the <NUM> module extends vertically above the first floor 60E of the <NUM> module and the second floor <NUM> of the <NUM> module, and extends above the <NUM>,<NUM> square meter footprint of the manufacturing wing. Together, the first floor 60E of the <NUM> module, the second floor <NUM> of the <NUM> module, and the third floor <NUM> of the <NUM> module have a combined area of <NUM>,<NUM> square meters.

<FIG> is a front perspective cutaway view of an exemplary embodiment of a customizable facility generally indicated at <NUM> according to the present disclosure. The customizable facility <NUM> layout can be configured for manufacturing in clean room settings. The customizable facility <NUM> utilizes a hybrid stick or frame build building and modular buildings with a centrally located utility hub (or central unit) <NUM>.

An outer shell (or shell) <NUM> encloses a central unit <NUM> and a plurality of modular units <NUM> adjacent to the central unit <NUM>. The outer shell <NUM> can be constructed according to traditional stick building or another method, such as, but not limited to, prefabricated modules. For example, the outer shell <NUM> can be fabricated from a steel structure using traditional building methods. The outer shell <NUM> can be supported on footings secured in the ground. The outer shell <NUM> is weatherproof.

The shell <NUM> includes side walls <NUM> that are dimensioned and configured to encircle one or more central units <NUM> and one or more modular units <NUM> included in the customizable facility <NUM>, and described in more detail below. A roof <NUM> is secured to upper edges of the side walls <NUM>, with the roof <NUM> extending over the central unit(s) <NUM> and the modular unit(s) <NUM>. Thus, the side walls <NUM> and the roof <NUM> enclose the central unit(s) <NUM> and the modular unit(s) <NUM>, which are positioned within the shell <NUM>. The central unit(s) <NUM> and the modular unit(s) <NUM> may be supported on a floor <NUM> of the shell <NUM> or on another support surface on which the shell <NUM> is secured. The customizable facility <NUM> provides a partially-modular (what could be called a modular stick build) method that includes a basic superstructure that is then filled in with modular type elements.

Within the shell <NUM>, the customizable facility <NUM> of <FIG> includes at least one central unit <NUM>, which each may be referred to as a Central Utility Bay (CUB). The central unit <NUM> provides central utilities in <FIG>. As shown, the CUB <NUM> is in the middle of the structure with modular units <NUM>, which may be referred to as manufacturing pods, which stem from the CUB <NUM> (or from a plurality of CUBs). In <FIG>, the modular units <NUM> are fermentation modules. The customizable facility <NUM> is easily expandable and scalable, and the pod/modular approach (i.e., a hub and spoke type approach) allows the different modules to produce completely different products in the same customizable facility <NUM>.

For example, in a first fermentation module, such as the fermentation module on the left of <FIG>, a user could be manufacturing one type of product, such as a monoclonal antibody product derived from a mammalian cell line. In a second module, such as the fermentation module on the right of <FIG>, the user could manufacture a completely different product, such as a microbial product. The customizable facility <NUM> of the present disclosure is capable of supporting multiple product lines simultaneously and multiple customers from a single, expandable superstructure.

<FIG> shows reactors <NUM> supported within the customizable facility <NUM>. The customizable facility <NUM> can support any desired and suitable vessel volume. For example, in some aspects such as that shown in <FIG>, the facility <NUM> can be configured to contain up to <NUM>,<NUM> Liter production vessels, and storage vessels (e.g., harvest) in excess of <NUM>,<NUM> liters (e.g., <NUM>,<NUM> - <NUM>,<NUM> liters). For example, the customizable facility <NUM> can be dimensioned and configured to support vessels <NUM> having a volume of about <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters and/or <NUM>,<NUM> liters. Vessels <NUM> having other volumes can also be supported.

Scaffolding <NUM> and corridors <NUM> allow users of the facility <NUM> to access the central unit (central utility) <NUM> and the modular units (fermentation, etc. modules) <NUM>. As shown in <FIG>, the scaffolding <NUM> is positioned within the shell <NUM>.

In some embodiments, one or more central units (CUBs) <NUM> and the one or more modular units <NUM> are arranged in a hub and spoke arrangement.

Any typical manufacturing and clean room equipment can be included in the customizable facility <NUM>, and the customizable facility <NUM> can be fully suitable for cGMP processes.

Examples of some equipment that can be fit in the facility <NUM> include, but are not limited to: bioreactor, disc stack centrifuge, tangential flow filtration (TFF) skid, depth filtration skid, in-line dilution skid, chromatography columns with associated control equipment, media tank, harvest tank, purification vessels, depth filter holders, water softening and dechlorination system, clean steam generator, water for injection (WFI) storage tank, WFI break tank, WFI still, cooling towers, switchboard, emergency generator, chiller, hydronic pumps, autoclave, air handling units, process waste neutralization (such as a fiberglass reinforced plastic (FRP)), biowaste collection and inactivation system, clean-in-place systems, glass washer, and/or other equipment.

Bioreactors in the customizable facility <NUM> of the present disclosure can have ground based reactors <NUM> as is shown in <FIG>. Alternatively, the bioreactors <NUM> could be suspended from the structure itself. For example, the bioreactors <NUM> could be suspended from one or more of the modular units <NUM>.

The shell <NUM> of <FIG> encloses a warehouse area <NUM> towards the back right of the facility <NUM>. The warehouse area <NUM> within this facility <NUM> could also suite high bay applications, such as a <NUM> foot tall warehouse having an automated search and retrieval system (ASARS).

The customizable facility <NUM> can include one or more central unit <NUM> and one or more modular unit <NUM>. In some embodiments, each modular unit <NUM> is selected from the group of: a fermentation or cell culture unit, a pre-viral unit, a post-viral unit, a utility yard, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a fill-finish unit, a dosage formulation unit, and a packaging unit. The space allocated for each modular unit can be divided further as needed to fit specific processing requirements.

In some embodiments, at least one of the modular unit(s) <NUM> is a clean room.

<FIG> shows a perspective view of a set of a central unit <NUM> and modular units <NUM> arranged in an H-shaped layout <NUM>. The position of each modular unit <NUM> can be adjusted to best fit processing requirements.

<FIG> and <FIG> show an embodiment of a customizable facility in which a central unit <NUM> and a set of eight modular units, configured as purification units 116A and fermentation units 116B, are arranged in an H-shaped layout <NUM> when viewed from above. The shell <NUM> is not shown in these views. The plan view of <FIG> shows a central unit (labeled as a central utilities building) <NUM> having a first row of modular units, configured as purification units 116A and fermentation units 116B, arranged in a linear array <NUM> adjacent to a first side <NUM> of the central unit <NUM>, and a second row of modular units, configured as purification units 116A and fermentation units 116B, arranged in a linear array <NUM> adjacent to a second side <NUM> of the central unit <NUM>. The array <NUM> of modular units includes four modular units, with a first purification unit 116A at a first end of the array <NUM>, two fermentation units 116B at the middle of the array <NUM>, and a second purification unit 116A at a second end of the array <NUM>. Similarly, the array <NUM> of modular units includes four modular units, with a first purification unit 116A at a first end of the array <NUM>, two fermentation units 116B at the middle of the array <NUM>, and a second purification unit 116A at a second end of the array <NUM>.

The two fermentation units 116B of the first array <NUM> of modular units each include a side wall that is in direct facing engagement with a first side wall <NUM> of the central unit <NUM>. Similarly, the two fermentation units 116B of the second array <NUM> of modular units each include a side wall that is in direct facing engagement with a second side wall <NUM> of the central unit <NUM>. The purification units 116A are in direct facing relation with their respectively adjacent fermentation units 116B. Because of the direct facing engagement of the central unit <NUM> and the fermentation units 116B, the number of central units <NUM> and modular units that can fit within a shell <NUM> of a given size is increased. Likewise, the footprint of a shell <NUM> required to enclose a given set of central units <NUM> and modular units is decreased. Optionally, in some aspects the side walls of the fermentation units 116B (or other modular units) need not be in direct facing engagement but could be spaced so as to provide any desired footprint.

The modular unit(s) <NUM> and the central unit(s) <NUM> can be arranged to facilitate manufacture of a plurality of products simultaneously. The modular unit(s) <NUM> and central unit(s) <NUM> are arranged to efficiently share resources between the manufacturing lines of the respective products. For example, in some embodiments, the central unit <NUM> contains at least one of: a power generator, plumbing lines, power lines, and other resources that can be shared by the modular units <NUM>. Additionally, the modular unit(s) <NUM> and the central unit(s) <NUM> can be arranged to facilitate future expansion of manufacturing capacity. For example, a single modular unit <NUM> can be utilized initially, with ability to add additional modular units <NUM> at a later time with minimal impact to existing operations.

In some embodiments, each of the modular units <NUM> includes its own respective heating, ventilation, and air conditioning (HVAC) system, as required for operation and segregation.

In some embodiments, the hub and spoke arrangement can resemble the letter H, such as in the plan view of <FIG>. In other embodiments, the hub and spoke arrangement does not resemble the letter H. Other shapes are possible, including but not limited to: a square, a rectangle, a pentagon, and other geometric shapes, so long as it has a central unit (a central utility bay) with at least one modular unit extending from there. Additional shapes are possible, for example, as shown in <FIG>. In some embodiments, for example, a linear "spine" shape can be used or an "E" shape can be used such that the hub and spoke arrangement resembles the letter E.

In some embodiments, the central unit <NUM> is not at the center of the arrangement of the central unit <NUM> and the modular units <NUM>. The arrangement of the modular units <NUM> and the central unit <NUM> is preferably configured to reduce the number of modular units <NUM> required for a given set of manufacturing lines.

The modular units <NUM> can be segmented off from each other to reduce cross-contamination of product or suites.

<FIG> shows a plan view of another preferred embodiment of the customizable facility <NUM> of the present disclosure. Two central units <NUM> are located towards the bottom center of the plan view of the structure shown in <FIG>, and are positioned between shared corridors <NUM> that extend alongside walls of the central units <NUM>. To the left of the central units <NUM> is a grouping of six modular units. This grouping includes two pre-viral units 116C, two post-viral units 116D, and two fermentation units 116B. To the right of the central units <NUM> as shown in <FIG> is a grouping of six modular units, including two pre-viral units 116C, two post-viral units 116D, and two fermentation units 116B. This configuration is designed to expand additional capability as needed (e.g., see <FIG> as example of an embodiment showing expansion options). Along the top of the facility <NUM> as shown in <FIG>, there are other modular units, including a utility yard unit 116E, two warehouse units 116F, two media/buffer facility units <NUM>, and office unit <NUM>, and two personnel access units 116J. Not shown in this figure is the capability to add independent buffer hold modular units directly above each purification unit. Shared corridors <NUM> extend along walls of the units, so that users can access each of the modular units of <FIG> and the central units <NUM> from a common corridor <NUM>.

The different units can have different classification levels based on grading standards. For example, different units can have different classification levels based on grading standards set by the United States Food and Drug Administration or grading standards set by <NPL>on. For example, the pre-viral units 116C, the post-viral units 116D, and the media/buffer facility units <NUM> in <FIG> are classified as "Grade C," while the fermentation units 116B are classified as "Grade D," according to the European Union standards, and the remaining units are unclassified. Other classifications for the units are possible, and can be selected according to user needs.

<FIG> shows another embodiment of a customizable facility <NUM> of the present disclosure. <FIG> includes a central unit (a central utilities building) <NUM> having corridors <NUM> for clean material and personnel on either side of the central unit <NUM>. The corridors <NUM> extend from a warehouse 116F at an upper end of the facility <NUM> shown in <FIG> and extend beyond the central unit <NUM> at the bottom of the facility. On outer sides of the respective corridors <NUM> are locker room units <NUM>, pre-viral units 116C, post-viral units 116D, and fermentation units 116B.

In an embodiment such as the one shown in <FIG>, the fermentation units 116B each have dimensions of <NUM> feet by <NUM> feet, and are <NUM> feet high. In an embodiment such as the one shown in <FIG>, the pre-viral units 116C may have dimensions of <NUM> feet by <NUM> feet, and are <NUM> feet high. In an embodiment such as the one shown in <FIG>, the post-viral units 116D each have dimensions of <NUM> feet by <NUM> feet, and are <NUM> feet high. In other embodiments, the units may have other dimensions.

<FIG> shows another embodiment of a customizable facility <NUM> of the present disclosure, with the shell <NUM> not shown. <FIG> includes five rows of zones. A first row (a top row) <NUM> in the plan view of <FIG> includes purification zones 117A. A second row <NUM> includes fermentation zones 117B. A third row <NUM> includes a central utilities zone <NUM>. A fourth row <NUM> includes fermentation zones 117B. A fifth row <NUM> includes purification zones 117A.

In some aspects, a customizable facility for manufacturing at least one pharmaceutical product may include at least one central unit and at least one modular unit, but the customizable facility does not include a shell. Each modular unit is in communication with the at least one central unit such that the at least one central unit provides utilities to each modular unit.

The zones in solid lines indicate a set of zones that may be provided in an initial configuration. In this initial configuration <NUM>, there are three purification zones (PURE <NUM>, PURE <NUM>, PURE <NUM>) 117A in the first row <NUM>, three fermentation zones (FERM <NUM>, FERM <NUM>, FERM <NUM>) 117B in the second row <NUM>, a central utilities zone (CENTRAL UTILITIES <NUM>) <NUM> in the third row <NUM>, three fermentation zones (FERM <NUM>, FERM <NUM>, FERM <NUM>) 117B in the fourth row <NUM>, and three purification zones (PURE <NUM>, PURE <NUM>, PURE <NUM>) 117A in the fifth row <NUM>.

A set of zones <NUM> could be added by extending an array of zones to the right. For example, two additional purification zones (PURE <NUM>, PURE <NUM>) 117A could be added to the first row <NUM>, two additional fermentation zones (FERM <NUM>, FERM <NUM>) 117B could be added to the second row <NUM>; additional central utilities zones <NUM> could be added to the third row <NUM>, two additional fermentation zones (FERM <NUM>, FERM <NUM>) 117B could be added to the fourth row <NUM>, and two additional purification zones (PURE <NUM>, PURE <NUM>) 117A could be added to the fifth row <NUM>. Arrows to the right, such as the arrow A between the fermentation zones 117B labeled FERM <NUM> and FERM N+<NUM>, indicate the direction of potential expansion of the arrangement of zones. Additional zones could be added to the respective rows as needed, and <FIG> shows a purification unit (PURE N+<NUM>) 117A at the end of the first row <NUM>, a fermentation zone (FERM N+<NUM>) 117B at the end of the second row <NUM>, a fermentation zone (FERM N) 117B along the direction of arrow B at the end of the fourth row <NUM>, and a purification zone (PURE N) 117A at the end of the fifth row <NUM>. The value of N can be an integer value selected by a user as needed, and is limited only by the internal dimensions of the shell <NUM> within which the modular units <NUM> and central unit(s) <NUM> are positioned.

The third row can be expanded by adding central utilities zones <NUM> to the third row <NUM> along an arrow C.

The zones of <FIG> are regions in that could each be a central unit or a modular unit (e.g., a fermentation unit, a purification unit, etc.), or regions that could support equipment for a unit. Where <FIG> shows a zone (such as zone FERM <NUM>), this zone can be subdivided into a fermentation unit FERM <NUM> and one or more hallways within the zone. In at least some zones, a unit can occupy the entire zone.

Modular units <NUM> disclosed herein may be further subdivided into sub-units. For example, a unit could have a pre-viral sub-unit and a post-viral sub-unit. The post-viral sub-unit is virus-free.

In relation to <FIG>, although the figures show views that are divided into regions that are described as units, the regions of the views can designate zones (such as a purification zone, a fermentation zone, etc.), which each include a unit and one or more hallways for connecting units.

<FIG> illustrates another example embodiment of a facility <NUM> in which a central unit <NUM> is in the shape of a linear "spine" with a plurality of modules <NUM> emanating from the spine. In this embodiment, the modules <NUM> can be added subsequently in multiple construction phases such that the facility is expanded over time.

According to an aspect of the present disclosure, a method of assembling a facility for manufacturing at least one pharmaceutical product may include providing a shell, positioning at least one central unit at least partially within the shell, and positioning at least one modular unit at least partially within the shell.

The fermentation unit 116B houses equipment suitable for cell culture and/or fermentation. For example, equipment for cell culture and fermentation include, but are not limited to, bioreactors (e.g., suitable for culturing cells or fermentation), tanks (e.g., suitable for housing cells, media or products produced by cells), decanting apparatus, centrifuges, pumps, and other equipment useful for product recovery. Refold tanks and microfiltration units would be included for microbial fermentation processes.

In one embodiment, the fermentation unit 116B contains one or more bioreactor units suitable for culturing cells. A bioreactor unit can perform one or more, or all, of the following: feeding of nutrients and/or carbon sources, injection of suitable gas (e.g., oxygen), flow of fermentation or cell culture medium, separation of gas and liquid phases, maintenance of growth temperature, maintenance of pH level, agitation (e.g., stirring), and/or cleaning/sterilizing. The fermentation unit may contain one, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, or <NUM>, or more bioreactors. In various embodiments, the bioreactor is suitable for batch, semi fed-batch, fed-batch, perfusion, and/or continuous fermentation processes. In one embodiment, the bioreactor is a stirred tank reactor. In one embodiment, the bioreactor is an airlift reactor. In one embodiment, the bioreactor can have a volume between about <NUM> milliliters and about <NUM>,<NUM> liters. Non-limiting examples include a volume of <NUM> milliliters, <NUM> milliliters, <NUM> milliliters, <NUM> milliliters, <NUM> liter, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, or <NUM>,<NUM> liters.

In one embodiment, the bioreactor is suitable for culturing suspension cells or anchorage-dependent (adherent) cells. In one embodiment, the fermentation suite is suitable for cell therapy and/or viral therapy operations. In one embodiment, the bioreactor is suitable for culturing prokaryotic cells or eukaryotic cells. Examples of cells include, but are not limited to, bacterial cells (e.g., E. pastoris), yeast cells (e.g., S. cerevisae, T. reesei), plant cells, insect cells (e.g., Sf9), Chinese hamster ovary cells (CHO, and any genetically modified or derived CHO cell line), mouse cells (e.g., mouse embryonic fibroblasts, cells derived from mouse cancer models), human cells (e.g., cells from any tissue or organ, cells from a cancer or other diseased cell line, stem cell), hybridoma cells, or other genetically modified or hybrid cells. In one embodiment, the cells express or produce a product, such as a recombinant therapeutic or diagnostic product. Examples of products produced by cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), or lipid-encapsulated particles (e.g., exosomes, virus-like particles). In embodiments, the fermentation unit also contains equipment for separation, purification, and isolation of such products from the cells. In one embodiment, the facility and/or bioreactor can be used for producing biosimilar products.

In embodiments, the fermentation unit is in compliance with good manufacturing process and biological safety standards. In one embodiment, the fermentation unit is compliant with biosafety level <NUM> (BSL1), biosafety level <NUM> (BSL2), biosafety level <NUM> (BSL3), or biosafety level <NUM> (BSL4).

The fermentation unit can comprise sub-compartments in which each sub-compartment can be used to perform a different function or aspect that supports the cell culture, fermentation, and production processes. By way of example, the fermentation unit comprises a sub-compartment that houses one or more bioreactors, a sub-compartment that houses equipment for product recovery, a sub-compartment for inoclum, and a sub-compartment for cleaning and decontamination of equipment and the operators handling such equipment.

The purification units 116A discussed above are examples of downstream processing units.

As one example, a standard downstream processing (DSP) unit includes pre-viral separation and post-viral separation sub-units. While viral reduction does occur throughout a typical mammalian cell derived protein purification, the critical viral reduction step is considered to be the appropriate point for spatial segregation with the post-viral separation sub-unit to be considered essentially virus free. The post-viral separation sub-unit houses equipment and utilities suitable for any one of the following: ultrafiltration (tangential filtration), normal filtration, chromatography, formulation, titration, mixing, concentration, buffer exchange, bulk drug substance container filling and freezing.

The descriptions of the various embodiments and/or examples of the present disclosure have been presented for purposes of illustration, but are not intended to be exhaustive or limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terminology used herein was chosen to best explain the principles of the embodiments, the practical application or technical improvement over technologies found in the marketplace, or to enable others of ordinary skill in the art to understand the embodiments disclosed herein.

The descriptions of the various embodiments of the present disclosure can be utilized in the production of pharmaceuticals and biopharmaceutical products. The devices, facilities and methods described herein are suitable for culturing any desired cell line including prokaryotic and/or eukaryotic cell lines. Further, in embodiments, the devices, facilities and methods are suitable for culturing suspension cells or anchorage-dependent (adherent) cells and are suitable for production operations configured for production of pharmaceutical and biopharmaceutical products-such as polypeptide products, nucleic acid products (for example DNA or RNA), or cells and/or viruses such as those used in cellular and/or viral therapies.

In embodiments, the cells express or produce a product, such as a recombinant therapeutic or diagnostic product. As described in more detail below, examples of products produced by cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), antibody mimetics (polypeptide molecules that bind specifically to antigens but that are not structurally related to antibodies such as e.g. DARPins, affibodies, adnectins, or IgNARs), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), viral therapeutics (e.g., anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy), cell therapeutics (e.g., pluripotent stem cells, mesenchymal stem cells and adult stem cells), vaccines or lipid-encapsulated particles (e.g., exosomes, virus-like particles), RNA (such as e.g. siRNA) or DNA (such as e.g. plasmid DNA), antibiotics or amino acids. In embodiments, the devices, facilities and methods can be used for producing biosimilars.

As mentioned, in embodiments, devices, facilities and methods allow for the production of eukaryotic cells, e.g., mammalian cells or lower eukaryotic cells such as for example yeast cells or filamentous fungi cells, or prokaryotic cells such as Gram-positive or Gram-negative cells and/or products of the eukaryotic or prokaryotic cells, e.g., proteins, peptides, antibiotics, amino acids, nucleic acids (such as DNA or RNA), synthesised by the eukaryotic cells in a large-scale manner. Unless stated otherwise herein, the devices, facilities, and methods can include any desired volume or production capacity including but not limited to bench-scale, pilot-scale, and full production scale capacities.

Moreover and unless stated otherwise herein, the devices, facilities, and methods can include any suitable reactor(s) including but not limited to stirred tank, airlift, fiber, microfiber, hollow fiber, ceramic matrix, fluidized bed, fixed bed, and/or spouted bed bioreactors. As used herein, "reactor" can include a fermentor or fermentation unit, or any other reaction vessel and the term "reactor" is used interchangeably with "fermentor. " For example, in some aspects, an example bioreactor unit can perform one or more, or all, of the following: feeding of nutrients and/or carbon sources, injection of suitable gas (e.g., oxygen), inlet and outlet flow of fermentation or cell culture medium, separation of gas and liquid phases, maintenance of temperature, maintenance of oxygen and CO2 levels, maintenance of pH level, agitation (e.g., stirring), and/or cleaning/sterilizing. Example reactor units, such as a fermentation unit, may contain multiple reactors within the unit, for example the unit can have <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, or <NUM>, or more bioreactors in each unit and/or a facility may contain multiple units having a single or multiple reactors within the facility. In various embodiments, the bioreactor can be suitable for batch, semi fed-batch, fed-batch, perfusion, and/or a continuous fermentation processes. Any suitable reactor diameter can be used. In embodiments, the bioreactor can have a volume between about <NUM> and about <NUM>,<NUM>. Non-limiting examples include a volume of <NUM> milliliters, <NUM> milliliters, <NUM> milliliters, <NUM> milliliters, <NUM> liter, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, <NUM>,<NUM> liters, and/or <NUM>,<NUM> liters. Additionally, suitable reactors can be multi-use, single-use, disposable, or non-disposable and can be formed of any suitable material including metal alloys such as stainless steel (e.g., <NUM> or any other suitable stainless steel) and Inconel, plastics, and/or glass.

In embodiments and unless stated otherwise herein, the devices, facilities, and methods described herein can also include any suitable unit operation and/or equipment not otherwise mentioned, such as operations and/or equipment for separation, purification, and isolation of such products. Any suitable facility and environment can be used, such as traditional stick-built facilities, modular, mobile and temporary facilities, or any other suitable construction, facility, and/or layout. For example, in some embodiments modular clean-rooms can be used. Additionally and unless otherwise stated, the devices, systems, and methods described herein can be housed and/or performed in a single location or facility or alternatively be housed and/or performed at separate or multiple locations and/or facilities.

By way of non-limiting examples and without limitation, <CIT>; <CIT>; <CIT>; <CIT>; and <CIT>; <CIT>; and <CIT>, which are hereby incorporated by reference in their entirety, describe example facilities, equipment, and/or systems that may be suitable.

In embodiments, the cells are eukaryotic cells, e.g., mammalian cells. The mammalian cells can be for example human or rodent or bovine cell lines or cell strains. Examples of such cells, cell lines or cell strains are e.g. mouse myeloma (NSO)-cell lines, Chinese hamster ovary (CHO)-cell lines, HT1080, H9, HepG2, MCF7, MDBK Jurkat, NIH3T3, PC12, BHK (baby hamster kidney cell), VERO, SP2/<NUM>, YB2/<NUM>, Y0, C127, L cell, COS, e.g., COS1 and COS7, QC1-<NUM>,HEK-<NUM>, VERO, PER. C6, HeLA, EBl, EB2, EB3, oncolytic or hybridoma-cell lines. Preferably the mammalian cells are CHO-cell lines. In one embodiment, the cell is a CHO cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knock-out cell, a CHO FUT8 GS knock-out cell, a CHOZN, or a CHO-derived cell. The CHO GS knock-out cell (e.g., GSKO cell) is, for example, a CHO-K1 SV GS knockout cell. The CHO FUT8 knockout cell is, for example, the Potelligent® CHOK1 SV (Lonza Biologics, Inc. Eukaryotic cells can also be avian cells, cell lines or cell strains, such as for example, EBx® cells, EB14, EB24, EB26, EB66, or EBvl3.

In one embodiment, the eukaryotic cells are stem cells. The stem cells can be, for example, pluripotent stem cells, including embryonic stem cells (ESCs), adult stem cells, induced pluripotent stem cells (iPSCs), tissue specific stem cells (e.g., hematopoietic stem cells) and mesenchymal stem cells (MSCs).

In one embodiment, the cell is a differentiated form of any of the cells described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.

In embodiments, the cell is a hepatocyte such as a human hepatocyte, animal hepatocyte, or a non-parenchymal cell. For example, the cell can be a plateable metabolism qualified human hepatocyte, a plateable induction qualified human hepatocyte, plateable Qualyst Transporter Certified™ human hepatocyte, suspension qualified human hepatocyte (including <NUM>-donor and <NUM>-donor pooled hepatocytes), human hepatic kupffer cells, human hepatic stellate cells, dog hepatocytes (including single and pooled Beagle hepatocytes), mouse hepatocytes (including CD-<NUM> and C57BI/<NUM> hepatocytes), rat hepatocytes (including Sprague-Dawley, Wistar Han, and Wistar hepatocytes), monkey hepatocytes (including Cynomolgus or Rhesus monkey hepatocytes), cat hepatocytes (including Domestic Shorthair hepatocytes), and rabbit hepatocytes (including New Zealand White hepatocytes). Example hepatocytes are commercially available from Triangle Research Labs, LLC, <NUM> Davis Drive Research Triangle Park, North Carolina, USA <NUM>.

In one embodiment, the eukaryotic cell is a lower eukaryotic cell such as e.g. a yeast cell (e.g., Pichia genus (e.g. Pichia pastoris, Pichia methanolica, Pichia kluyveri, and Pichia angusta), Komagataella genus (e.g. Komagataella pastoris, Komagataella pseudopastoris or Komagataella phaffii), Saccharomyces genus (e.g. Saccharomyces cerevisae, cerevisiae, Saccharomyces kluyveri, Saccharomyces uvarum), Kluyveromyces genus (e.g. Kluyveromyces lactis, Kluyveromyces marxianus), the Candida genus (e.g. Candida utilis, Candida cacaoi, Candida boidinii,), the Geotrichum genus (e.g. Geotrichum fermentans), Hansenula polymorpha, Yarrowia lipolytica, or Schizosaccharomyces pombe,. Preferred is the species Pichia pastoris. Examples for Pichia pastoris strains are X33, GS115, KM71, KM71H; and CBS7435.

In one embodiment, the eukaryotic cell is a fungal cell (e.g. Aspergillus (such as A. fumigatus, A. nidula), Acremonium (such as A. thermophilum), Chaetomium (such as C. thermophilum), Chrysosporium (such as C. thermophile), Cordyceps (such as C. militaris), Corynascus, Ctenomyces, Fusarium (such as F. oxysporum), Glomerella (such as G. graminicola), Hypocrea (such as H. jecorina), Magnaporthe (such as M. orzyae), Myceliophthora (such as M. thermophile), Nectria (such as N. heamatococca), Neurospora (such as N. crassa), Penicillium, Sporotrichum (such as S. thermophile), Thielavia (such as T. terrestris, T. heterothallica), Trichoderma (such as T. reesei), or Verticillium (such as V.

In one embodiment, the eukaryotic cell is an insect cell (e.g., Sf9, Mimic™ Sf9, Sf21, High Five™ (BT1-TN-5B1-<NUM>), or BT1-Ea88 cells), an algae cell (e.g., of the genus Amphora, Bacillariophyceae, Dunaliella, Chlorella, Chlamydomonas, Cyanophyta (cyanobacteria), Nannochloropsis, Spirulina,or Ochromonas), or a plant cell (e.g., cells from monocotyledonous plants (e.g., maize, rice, wheat, or Setaria), or from a dicotyledonous plants (e.g., cassava, potato, soybean, tomato, tobacco, alfalfa, Physcomitrella patens or Arabidopsis).

In one embodiment, the cell is a bacterial or prokaryotic cell.

In embodiments, the prokaryotic cell is a Gram-positive cells such as Bacillus, Streptomyces Streptococcus, Staphylococcus or Lactobacillus. Bacillus that can be used is, e.g. the B. subtilis, B. amyloliquefaciens, B. licheniformis, B. natto, or B. megaterium. In embodiments, the cell is B. subtilis, such as B. subtilis 3NA and B. subtilis <NUM>. Bacillus is obtainable from, e.g., the Bacillus Genetic Stock Center , Biological Sciences <NUM>, <NUM> West <NUM>th Avenue, Columbus OH <NUM>-<NUM>.

In one embodiment, the prokaryotic cell is a Gram-negative cell, such as Salmonella spp. or Escherichia coli, such as e.g., TG1, TG2, W3110, DH1, DHB4, DH5a, HMS <NUM>, HMS174 (DE3), NM533, C600, HB101, JM109, MC4100, XL1-Blue and Origami, as well as those derived from E. coli B-strains, such as for example BL-<NUM> or BL21 (DE3), all of which are commercially available.

Suitable host cells are commercially available, for example, from culture collections such as the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany) or the American Type Culture Collection (ATCC).

In embodiments, the cultured cells are used to produce proteins e.g., antibodies, e.g., monoclonal antibodies, and/or recombinant proteins, for therapeutic use. In embodiments, the cultured cells produce peptides, amino acids, fatty acids or other useful biochemical intermediates or metabolites. For example, in embodiments, molecules having a molecular weight of about <NUM> daltons to greater than about <NUM>,<NUM> daltons can be produced. In embodiments, these molecules can have a range of complexity and can include posttranslational modifications including glycosylation.

In embodiments, the protein is, e.g., BOTOX, Myobloc, Neurobloc, Dysport (or other serotypes of botulinum neurotoxins), alglucosidase alpha, daptomycin, YH-<NUM>, choriogonadotropin alpha, filgrastim, cetrorelix, interleukin-<NUM>, aldesleukin, teceleulin, denileukin diftitox, interferon alpha-n3 (injection), interferon alpha-nl, DL-<NUM>, interferon, Suntory (gamma-1a), interferon gamma, thymosin alpha <NUM>, tasonermin, DigiFab, ViperaTAb, EchiTAb, CroFab, nesiritide, abatacept, alefacept, Rebif, eptoterminalfa, teriparatide (osteoporosis), calcitonin injectable (bone disease), calcitonin (nasal, osteoporosis), etanercept, hemoglobin glutamer <NUM> (bovine), drotrecogin alpha, collagenase, carperitide, recombinant human epidermal growth factor (topical gel, wound healing), DWP401, darbepoetin alpha, epoetin omega, epoetin beta, epoetin alpha, desirudin, lepirudin, bivalirudin, nonacog alpha, Mononine, eptacog alpha (activated), recombinant Factor VIII+VWF, Recombinate, recombinant Factor VIII, Factor VIII (recombinant), Alphnmate, octocog alpha, Factor VIII, palifermin,Indikinase, tenecteplase, alteplase, pamiteplase, reteplase, nateplase, monteplase, follitropin alpha, rFSH, hpFSH, micafungin, pegfilgrastim, lenograstim, nartograstim, sermorelin, glucagon, exenatide, pramlintide, iniglucerase, galsulfase, Leucotropin, molgramostim, triptorelin acetate, histrelin (subcutaneous implant, Hydron), deslorelin, histrelin, nafarelin, leuprolide sustained release depot (ATRIGEL), leuprolide implant (DUROS), goserelin, Eutropin, KP-<NUM> program, somatropin, mecasermin (growth failure), enlfavirtide, Org-<NUM>, insulin glargine, insulin glulisine, insulin (inhaled), insulin lispro, insulin deternir, insulin (buccal, RapidMist), mecasermin rinfabate, anakinra, celmoleukin, <NUM> mTc-apcitide injection, myelopid, Betaseron, glatiramer acetate, Gepon, sargramostim, oprelvekin, human leukocyte-derived alpha interferons, Bilive, insulin (recombinant), recombinant human insulin, insulin aspart, mecasenin, Roferon-A, interferon-alpha <NUM>, Alfaferone, interferon alfacon-<NUM>, interferon alpha, Avonex' recombinant human luteinizing hormone, dornase alpha, trafermin, ziconotide, taltirelin, diboterminalfa, atosiban, becaplermin, eptifibatide, Zemaira, CTC-<NUM>, Shanvac-B, HPV vaccine (quadrivalent), octreotide, lanreotide, ancestirn, agalsidase beta, agalsidase alpha, laronidase, prezatide copper acetate (topical gel), rasburicase, ranibizumab, Actimmune, PEG-Intron, Tricomin, recombinant house dust mite allergy desensitization injection, recombinant human parathyroid hormone (PTH) <NUM>-<NUM> (sc, osteoporosis), epoetin delta, transgenic antithrombin III, Granditropin, Vitrase, recombinant insulin, interferon-alpha (oral lozenge), GEM-<NUM>, vapreotide, idursulfase, omnapatrilat, recombinant serum albumin, certolizumab pegol, glucarpidase, human recombinant C1 esterase inhibitor (angioedema), lanoteplase, recombinant human growth hormone, enfuvirtide (needle-free injection, Biojector <NUM>), VGV-<NUM>, interferon (alpha), lucinactant, aviptadil (inhaled, pulmonary disease), icatibant, ecallantide, omiganan, Aurograb, pexigananacetate, ADI-PEG-<NUM>, LDI-<NUM>, degarelix, cintredelinbesudotox, Favld, MDX-<NUM>, ISAtx-<NUM>, liraglutide, teriparatide (osteoporosis), tifacogin, AA4500, T4N5 liposome lotion, catumaxomab, DWP413, ART-<NUM>, Chrysalin, desmoteplase, amediplase, corifollitropinalpha, TH-<NUM>, teduglutide, Diamyd, DWP-<NUM>, growth hormone (sustained release injection), recombinant G-CSF, insulin (inhaled, AIR), insulin (inhaled, Technosphere), insulin (inhaled, AERx), RGN-<NUM>, DiaPep277, interferon beta (hepatitis C viral infection (HCV)), interferon alpha-n3 (oral), belatacept, transdermal insulin patches, AMG-<NUM>, MBP-<NUM>, Xerecept, opebacan, AIDSVAX, GV-<NUM>, LymphoScan, ranpirnase, Lipoxysan, lusupultide, MP52 (beta-tricalciumphosphate carrier, bone regeneration), melanoma vaccine, sipuleucel-T, CTP-<NUM>, Insegia, vitespen, human thrombin (frozen, surgical bleeding), thrombin, TransMID, alfimeprase, Puricase, terlipressin (intravenous, hepatorenal syndrome), EUR-<NUM>, recombinant FGF-I (injectable, vascular disease), BDM-E, rotigaptide, ETC-<NUM>, P-<NUM>, MBI-594AN, duramycin (inhaled, cystic fibrosis), SCV-<NUM>, OPI-<NUM>, Endostatin, Angiostatin, ABT-<NUM>, Bowman Birk Inhibitor Concentrate, XMP-<NUM>, <NUM> mTc-Hynic-Annexin V, kahalalide F, CTCE-<NUM>, teverelix (extended release), ozarelix, rornidepsin, BAY-<NUM>, interleukin4, PRX-<NUM>, Pepscan, iboctadekin, rhlactoferrin, TRU-<NUM>, IL-<NUM>, ATN-<NUM>, cilengitide, Albuferon, Biphasix, IRX-<NUM>, omega interferon, PCK-<NUM>, CAP-<NUM>, pasireotide, huN901-DMI, ovarian cancer immunotherapeutic vaccine, SB-<NUM>, Oncovax-CL, OncoVax-P, BLP-<NUM>, CerVax-<NUM>, multi-epitope peptide melanoma vaccine (MART-<NUM>, gp100, tyrosinase), nemifitide, rAAT (inhaled), rAAT (dermatological), CGRP (inhaled, asthma), pegsunercept, thymosinbeta4, plitidepsin, GTP-<NUM>, ramoplanin, GRASPA, OBI-<NUM>, AC-<NUM>, salmon calcitonin (oral, eligen), calcitonin (oral, osteoporosis), examorelin, capromorelin, Cardeva, velafermin, 131I-TM-<NUM>, KK-<NUM>, T-<NUM>, ularitide, depelestat, hematide, Chrysalin (topical), rNAPc2, recombinant Factor V111 (PEGylated liposomal), bFGF, PEGylated recombinant staphylokinase variant, V-<NUM>, SonoLysis Prolyse, NeuroVax, CZEN-<NUM>, islet cell neogenesis therapy, rGLP-<NUM>, BIM-<NUM>, LY-<NUM>, exenatide (controlled release, Medisorb), AVE-<NUM>, GA-GCB, avorelin, ACM-<NUM>, linaclotid eacetate, CETi-<NUM>, Hemospan, VAL (injectable), fast-acting insulin (injectable, Viadel), intranasal insulin, insulin (inhaled), insulin (oral, eligen), recombinant methionyl human leptin, pitrakinra subcutaneous injection, eczema), pitrakinra (inhaled dry powder, asthma), Multikine, RG-<NUM>, MM-<NUM>, NBI-<NUM>, AT-<NUM>, PI-<NUM>, Org-<NUM>, Cpn10 (autoimmune diseases/inflammation), talactoferrin (topical), rEV-<NUM> (ophthalmic), rEV-<NUM> (respiratory disease), oral recombinant human insulin (diabetes), RPI-<NUM>, oprelvekin (oral), CYT-<NUM> CTLA4-Ig, DTY-<NUM>, valategrast, interferon alpha-n3 (topical), IRX-<NUM>, RDP-<NUM>, Tauferon, bile salt stimulated lipase, Merispase, alaline phosphatase, EP-2104R, Melanotan-II, bremelanotide, ATL-<NUM>, recombinant human microplasmin, AX-<NUM>, SEMAX, ACV-<NUM>, Xen-<NUM>, CJC-<NUM>, dynorphin A, SI-<NUM>, LAB GHRH, AER-<NUM>, BGC-<NUM>, malaria vaccine (virosomes, PeviPRO), ALTU-<NUM>, parvovirus B19 vaccine, influenza vaccine (recombinant neuraminidase), malaria/HBV vaccine, anthrax vaccine, Vacc-5q, Vacc-4x, HIV vaccine (oral), HPV vaccine, Tat Toxoid, YSPSL, CHS-<NUM>, PTH(<NUM>-<NUM>) liposomal cream (Novasome), Ostabolin-C, PTH analog (topical, psoriasis), MBRI-<NUM>, MTB72F vaccine (tuberculosis), MVA-Ag85A vaccine (tuberculosis), FARA04, BA-<NUM>, recombinant plague FIV vaccine, AG-<NUM>, OxSODrol, rBetV1, Der-p1/Der-p2/Der-p7 allergen-targeting vaccine (dust mite allergy), PR1 peptide antigen (leukemia), mutant ras vaccine, HPV-<NUM> E7 lipopeptide vaccine, labyrinthin vaccine (adenocarcinoma), CML vaccine, WT1-peptide vaccine (cancer), IDD-<NUM>, CDX-<NUM>, Pentrys, Norelin, CytoFab, P-<NUM>, VT-<NUM>, icrocaptide, telbermin (dermatological, diabetic foot ulcer), rupintrivir, reticulose, rGRF, HA, alpha-galactosidase A, ACE-<NUM>, ALTU-<NUM>, CGX-<NUM>, angiotensin therapeutic vaccine, D-4F, ETC-<NUM>, APP-<NUM>, rhMBL, SCV-<NUM> (oral, tuberculosis), DRF-<NUM>, ABT-<NUM>, ErbB2-specific immunotoxin (anticancer), DT3SSIL-<NUM>, TST-<NUM>, PRO-<NUM>, Combotox, cholecystokinin-B/gastrin-receptor binding peptides, 111In-hEGF, AE-<NUM>, trasnizumab-DM1, Antagonist G, IL-<NUM> (recombinant), PM-<NUM>, IMP-<NUM>, rhIGF-BP3, BLX-<NUM>, CUV-<NUM> (topical), L-<NUM> based radioimmunotherapeutics (cancer), Re-<NUM>-P-<NUM>, AMG-<NUM>, DC/<NUM>/KLH vaccine (cancer), VX-<NUM>, AVE-<NUM>, AC-<NUM>, NY-ESO-<NUM> vaccine (peptides), NA17. A2 peptides, melanoma vaccine (pulsed antigen therapeutic), prostate cancer vaccine, CBP-<NUM>, recombinant human lactoferrin (dry eye), FX-<NUM>, AP-<NUM>, WAP-8294A (injectable), ACP-HIP, SUN-<NUM>, peptide YY [<NUM>-<NUM>] (obesity, intranasal), FGLL, atacicept, BR3-Fc, BN-<NUM>, BA-<NUM>, human parathyroid hormone <NUM>-<NUM> (nasal, osteoporosis), F-<NUM>-CCR1, AT-<NUM> (celiac disease/diabetes), JPD-<NUM>, PTH(<NUM>-<NUM>) liposomal cream (Novasome), duramycin (ophthalmic, dry eye), CAB-<NUM>, CTCE-<NUM>, GlycoPEGylated erythropoietin, EPO-Fc, CNTO-<NUM>, AMG-<NUM>, JR-<NUM>, Factor XIII, aminocandin, PN-<NUM>, <NUM>, SUN-E7001, TH-<NUM>, BAY-<NUM>-<NUM>, teverelix (immediate release), EP-<NUM>, hGH (controlled release, Biosphere), OGP-I, sifuvirtide, TV4710, ALG-<NUM>, Org-<NUM>, rhCC10, F-<NUM>, thymopentin (pulmonary diseases), r(m)CRP, hepatoselective insulin, subalin, L19-IL-<NUM> fusion protein, elafin, NMK-<NUM>, ALTU-<NUM>, EN-<NUM>, rhTPO, thrombopoietin receptor agonist (thrombocytopenic disorders), AL-<NUM>, AL-<NUM>, nerve growth factor antagonists (pain), SLV-<NUM>, CGX-<NUM>, INNO-<NUM>, oral teriparatide (eligen), GEM-OS1, AC-<NUM>, PRX-<NUM>, LFn-p24 fusion vaccine (Therapore), EP-<NUM>, S pneumoniae pediatric vaccine, malaria vaccine, Neisseria meningitidis Group B vaccine, neonatal group B streptococcal vaccine, anthrax vaccine, HCV vaccine (gpE1+gpE2+MF-<NUM>), otitis media therapy, HCV vaccine (core antigen+ISCOMATRIX), hPTH(<NUM>-<NUM>) (transdermal, ViaDerm), <NUM>, SYN-<NUM>, PGN-<NUM>, aviscumnine, BIM-<NUM>, tuberculosis vaccine, multi-epitope tyrosinase peptide, cancer vaccine, enkastim, APC-<NUM>, GI-<NUM>, ACC-<NUM>, TTS-CD3, vascular-targeted TNF (solid tumors), desmopressin (buccal controlled-release), onercept, and TP-<NUM>.

In some embodiments, the polypeptide is adalimumab (HUMIRA), infliximab (REMICADE™), rituximab (RITUXAN™/MAB THERA™) etanercept (ENBREL™), bevacizumab (AVASTIN™), trastuzumab (HERCEPTIN™), pegrilgrastim (NEULASTA™), or any other suitable polypeptide including biosimilars and biobetters.

Other suitable polypeptides are those listed below and in Table <NUM> of <CIT> :.

In embodiments, the polypeptide is a hormone, blood clotting/coagulation factor, cytokine/growth factor, antibody molelcule, fusion protein, protein vaccine, or peptide as shown in Table <NUM>.

In embodiments, the protein is multispecific protein, e.g., a bispecific antibody as shown in Table <NUM>.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice of and/or for the testing of the present disclosure, the preferred materials and methods are described herein. In describing and claiming the present disclosure, the following terminology will be used according to how it is defined, where a definition is provided.

It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

By way of example, "a modular unit" can mean one modular unit or more than one modular unit.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the customizable facility of the present disclosure.

Claim 1:
A customizable facility (<NUM>; <NUM>; <NUM>) for manufacturing at least one pharmaceutical product, the customizable facility (<NUM>; <NUM>; <NUM>) comprising:
at least one central unit (<NUM>; <NUM>) positioned on a ground surface floor of the customizable facility; and
a plurality of modular units (<NUM>; 40A, 40B, 40C, 40D, 40E; <NUM>) in communication with the at least one central unit (<NUM>; <NUM>) such that the at least one central unit (<NUM>) provides shared utilities to the plurality of modular units (<NUM>; 40A, 40B, 40C, 40D, 40E; <NUM>), and
a shell (<NUM>; <NUM>), wherein the at least one central unit (<NUM>; <NUM>) is positioned at least partially within the shell (<NUM>; <NUM>) and the plurality of modular units (<NUM>; 40A, 40B, 40C, 40D,
40E; <NUM>) are positioned at least partially within the shell (<NUM>; <NUM>),
wherein the plurality of modular units (<NUM>; 40A, 40B, 40C, 40D, 40E; <NUM>) are arranged to maximize a number of modular units (<NUM>; 40A, 40B, 40C, 40D, 40E; <NUM>) within the shell (<NUM>; <NUM>) while minimizing a footprint of the shell (<NUM>; <NUM>),
characterized in that
the plurality of modular units (<NUM>, 40A; 40B; 40C; 40D; 40E; <NUM>) include a fermentation unit (116B), a a pre-viral unit (116C), a post-viral unit (116D), a utility space (116E), a warehouse (116F), a media buffer facility (<NUM>), an office (<NUM>), a personnel unit (116J), a fill-finish unit, a dosage formulation unit, a packaging unit, and at least one corridor connecting at least two of the modular units to one another, and at least one second corridor connecting at least two of the modular units of the second set of modular units to one another, wherein the at least one corridor and the at least one second corridor are connected to the warehouse unit (116F) disposed within the shell and
wherein the customizable facility comprises two manufacturing wings (22A, 22B), which are configured to contain modular units (<NUM>) for a product line and the different modular units (<NUM>) within the manufacturing wings (22A, 22B) can be used to produce completely different products in the same customizable facility (<NUM>) and
wherein additional modular units (<NUM>), an additional manufacturing wing or another component of the customizable facility are positioned horizontally adjacent to the first manufacturing
wing (22A) and/or the second manufacturing wing (22B).